Latest Pneumococcal conjugate vaccine Stories
A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa.
Successor to Prevnar is intended for infants, young children SILVER SPRING, Md., Feb. 24 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years.
The pneumococcal vaccine for infants and children introduced in 2000 caused a precipitous drop in infections until 2005, when serious illnesses began to rise again, especially infections caused by a strain of the pneumococcal bacteria called 19A, said researchers from Baylor College of Medicine and Texas Children's Hospital in a report in the current issue of the journal Pediatrics.
PATH supports FDA advancement of a key step in vaccine development SILVER SPRING, Md., Feb. 1 /PRNewswire-USNewswire/ -- The U.S.
On Monday, the UN released an outlined plan that would cost $39 billion to save 5.3 million children from dying of pneumonia worldwide.
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.
Many people who have died of H1N1 influenza in the United States had other bacterial infections that likely contributed to their deaths, health officials say.
COLLEGEVILLE, Pa., Sept.
NEW YORK, Sept.
- A transitional zone between two communities containing the characteristic species of each.